Stock Price & Analysis

The S1 support level for IMRX Stock is $1.44 ,The R1 resistant level for IMRX Stock is $1.73.

As of the end of day on 2025-03-07, the price of IMRX Stock was $1.509.

The target price for IMRX Stock according to analyst rating is 10.00, with the highest price target at 12.00 and the lowest at 8.00. Analysts have a Moderate Buy rating on IMRX Stock overall.

The market cap of IMRX is $47.2M.

Immuneering Corporation is a clinical-stage oncology company. The Company is engaged in the development of medicines for cancer patients with universal-RAS therapy. The Company’s lead product candidate, IMM-1-104, in under Phase I/IIa clinical trial in patients with advanced solid tumors harboring RAS mutations. IMM-1-104 is being developed as a once-daily oral monotherapy that aims to achieve universal-RAS activity through deep cyclic inhibition of the MAPK pathway. The Company’s second product candidate, IMM-6-415, aims to achieve universal-MAPK activity with an accelerated twice-daily oral dosing cadence, also through deep cyclic inhibition of the MAPK pathway. IMM-6-415 is in Investigational New Drug application (IND), enabling studies. Its pipeline also includes Trifecta MEK, RAS modulators and other small molecule drug discovery programs. The Company’s platform is enabled by two key elements: Bioinformatics and 3D Tumor Modeling.

IMRX has a total of 68 employees.